FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 705 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer July 26, 2018 A tribute to Professor Gordon McVie February 18, 2021 Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... December 9, 2020 A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... January 16, 2026 Load more HOT NEWS Soaring skin cancer cases hit a record high NHS lung cancer patients in England to get early access to... Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan
